Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma.
about
Cellularly active N-hydroxyurea FEN1 inhibitors block substrate entry to the active siteTemozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 ExpressionRecurrent Glioblastomas Reveal Molecular Subtypes Associated with Mechanistic Implications of Drug-ResistanceGenetic screens in human cells using the CRISPR-Cas9 systemMetabolomics of Therapy Response in Preclinical Glioblastoma: A Multi-Slice MRSI-Based Volumetric Analysis for Noninvasive Assessment of Temozolomide TreatmentRetinoblastoma Binding Protein 4 Modulates Temozolomide Sensitivity in Glioblastoma by Regulating DNA Repair Proteins.Temozolomide promotes genomic and phenotypic changes in glioblastoma cells.Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice.Current progress for the use of miRNAs in glioblastoma treatment.c-Myc-miR-29c-REV3L signalling pathway drives the acquisition of temozolomide resistance in glioblastoma.A stapled peptide antagonist of MDM2 carried by polymeric micelles sensitizes glioblastoma to temozolomide treatment through p53 activation.Upregulation of CYP17A1 by Sp1-mediated DNA demethylation confers temozolomide resistance through DHEA-mediated protection in glioma.Molecular dissection of the valproic acid effects on glioma cells.Endoplasmic reticulum stress-inducing drugs sensitize glioma cells to temozolomide through downregulation of MGMT, MPG, and Rad51Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles.Temozolomide and Pituitary Tumors: Current Understanding, Unresolved Issues, and Future Directions.
P2860
Q27727694-0BE577B0-1776-4CF1-946A-02E11F07F26CQ28550138-76321B5A-0CB8-4035-98BE-5C296AB365B5Q28550264-BA900E9F-000C-4261-92E5-778AF83B35ECQ29617411-834D5764-78DD-4733-9E55-4804852AFE6EQ33844943-0453739F-65B1-4FE7-9F94-47B88B56189EQ36723302-AC9B2E8C-A7A0-4D52-8FE2-C077ED106C39Q36875981-FA231B5B-7DBF-4687-AF89-6B880D8E3C76Q37731326-5C97A2C8-7AF0-4338-AE63-3BE9ECC11D14Q38102611-21394853-18E6-4466-85E2-CF6E87828597Q38829331-D27DBF46-8511-41B7-ACDC-BAC2CC7DE3D2Q38830917-7C198DFC-7561-4998-B352-6DEF662E084AQ41098467-55B1C886-9793-43D7-B062-E02E07CA5C9CQ41809551-C221EEE7-6CEC-4FE3-BEF1-EA60F32C764EQ42014579-DA8F6CEC-0E75-4AD0-B304-EB72E8358366Q47798259-BFD8D435-28A4-402A-986D-8566E2C942A5Q49387560-C5F779DB-5A7B-4BEA-8F35-BA05D840CBD7Q55370601-7C2F8D17-1B78-4EEA-8767-4D01CD21F712
P2860
Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Complex DNA repair pathways as ...... de resistance in glioblastoma.
@en
type
label
Complex DNA repair pathways as ...... de resistance in glioblastoma.
@en
prefLabel
Complex DNA repair pathways as ...... de resistance in glioblastoma.
@en
P2093
P2860
P356
P1476
Complex DNA repair pathways as ...... de resistance in glioblastoma.
@en
P2093
Akira Nakamizo
Hideki Murata
Koji Yoshimoto
Masahiro Mizoguchi
Nobuhiro Hata
Ryusuke Hatae
Tomio Sasaki
Toshiyuki Amano
P2860
P356
10.3389/FONC.2012.00186
P577
2012-12-05T00:00:00Z